Dynavax Technologies Corporation
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$24.9M
Doctors Paid
10,213
Transactions
19,385
2024 Total
$530,474
Payment Breakdown by Category
Research$22.5M (90.5%)
Consulting$1.7M (7.0%)
Food & Beverage$328,895 (1.3%)
Travel$19,600 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $22.5M | 1,688 | 90.5% |
| Consulting Fee | $1.7M | 443 | 7.0% |
| Food and Beverage | $328,895 | 17,208 | 1.3% |
| Current or prospective ownership or investment interest | $231,317 | 2 | 0.9% |
| Honoraria | $25,980 | 4 | 0.1% |
| Travel and Lodging | $19,600 | 34 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,875 | 4 | 0.1% |
| Grant | $3,916 | 1 | 0.0% |
| Education | $41.00 | 1 | 0.0% |
Payments by Type
Research
$22.5M
1,688 transactions
General
$2.4M
17,697 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2) | $6.2M | 0 | 10 |
| Post-Marketing Observational Surveillance Study to Evaluate the Occurrence of Acute Myocardial Infarction in Adults 18 Years of Age and Older Who Receive HEPLISAV-B Compared with Another Hepatitis B Vaccine | $5.6M | 0 | 9 |
| A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | $4.9M | 0 | 456 |
| HEPLISAV-B in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis | $1.4M | 2 | 693 |
| Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC | $1.3M | 0 | 103 |
| Post-Marketing Observational Surveillance Study to Evaluate the Incidence of New-Onset Immune-Mediated Diseases, Herpes Zoster, and Anaphylaxis in Adults 18 Years of Age and Older Who Receive HEPLISAV B Compared with Another Hepatitis B Vaccine | $917,085 | 0 | 1 |
| HEPLISAV-B Pregnancy Registry: an observational study on the safety of HEPLISAV-B exposure in pregnant women and their offspring | $745,434 | 0 | 4 |
| Post-marketing Study for Immune-Mediated, Herpes Zoster, and Anaphylaxis Events | $509,714 | 0 | 2 |
| Heplisav-B Post Marketing Study - Immune-mediated Diseases, Hepes Zoster and Anaphylaxis | $404,979 | 0 | 4 |
| A Phase 2, randomized, active-controlled, observer-blind, multicenter trial of the immunogenicity, safety and tolerability of rF1V vaccine with CpG 1018 adjuvant compared with rF1V vaccine alone in approximately 200 healthy volunteers between the ages of 18 and 55 years of age | $84,247 | 0 | 382 |
| Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients | $39,144 | 0 | 13 |
| HEPLISAV-B Revaccination for Previous Hepatitis B Vaccine Non-Responders (In Veterans) | $14,053 | 0 | 1 |
| Immunologic Efficacy of HEPLISAV-B Vaccine in Patients Undergoing Treatment with Immunosuppressive Medications | $7,983 | 0 | 5 |
| Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders | $7,729 | 0 | 1 |
| Evaluating the impact of an adjuvanted vaccine (HEPLISAV-B) in healthcare personnel previously vaccinated using the standard 3-dose Hepatitis B vaccine who failed to demonstrate seroprotection | $3,900 | 0 | 1 |
| ost-Marketing Observational Surveillance Study to Evaluate the Occurrence of Acute Myocardial Infarction in Adults 18 Years of Age and Older Who Receive HEPLISAV-B Compared with Another Hepatitis B Vaccine | $1,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Teck Ling, Md, MD | Internal Medicine | Palo Alto, CA | $900,376 | $0 |
| Dennis Carson, Md, MD | Rheumatology | La Jolla, CA | $310,751 | $0 |
| Dr. Sean Bennett, Md Phd, MD PHD | Research | Charlottesville, VA | $134,475 | $0 |
| Dr. Arun Jesudian, Md, MD | Internal Medicine | New York, NY | $73,239 | $0 |
| Peter Patriarca, M.d, M.D | Contractor | Bethesda, MD | $63,500 | $0 |
| Kwabena Ntoso, Md, MD | Nephrology | Philadelphia, PA | $53,609 | $0 |
| Robert Perrillo, M.d, M.D | Gastroenterology | Dallas, TX | $29,142 | $0 |
| Syeda Amna Husain, Md, MD | Pediatrics | Marlboro, NJ | $25,500 | $0 |
| David Weber, Md, MD | Pediatric Infectious Diseases | Chapel Hill, NC | $20,667 | $0 |
| Gregory Poland, M.d, M.D | Internal Medicine | Rochester, MN | $20,125 | $0 |
| Dr. Arthur Jeng, M.d, M.D | Infectious Disease | Sylmar, CA | $17,612 | $0 |
| Dr. Carolyn Bridges, M.d, M.D | Internal Medicine | Boise, ID | $15,606 | $0 |
| Dr. Tamera Coyne-Beasley, Md, MD | Pediatrics | Birmingham, AL | $15,490 | $0 |
| Myron Levin, Md, MD | Pediatric Infectious Diseases | Aurora, CO | $14,325 | $0 |
| Judith Feinberg, M.d, M.D | Internal Medicine | Cincinnati, OH | $14,000 | $0 |
| Mr. Mark Lee, Md, MD | Internal Medicine | Whittier, CA | $13,625 | $0 |
| Dr. Donald Middleton, Md, MD | Pediatrics | Pittsburgh, PA | $12,455 | $0 |
| Stanley Grogg, Do, DO | Pediatrics | Tulsa, OK | $12,256 | $0 |
| Darren Mcguire, Md, MD | Cardiovascular Disease | Dallas, TX | $11,750 | $0 |
| Dr. Elham Safani, Md, MD | Internal Medicine | Phoenix, AZ | $10,010 | $0 |
| Dr. Stanley Plotkin, Md, MD | Clinical & Laboratory Immunology | Doylestown, PA | $10,000 | $0 |
| Richard Manch, M.d, M.D | Gastroenterology | Glendale, AZ | $7,847 | $0 |
| David Kaelber, Md, MD | Pediatrics | Cleveland, OH | $6,600 | $0 |
| Dr. Walter Orenstein, Md, MD | Infectious Disease | Atlanta, GA | $5,600 | $0 |
| Laura Chow, Md, MD | Medical Oncology | Seattle, WA | $5,538 | $0 |
Ad
Top Products
- Heplisav-B $11.8M
- SD-101 $6.5M
Associated Products (6)
- Heplisav-B $11.8M
- SD-101 $6.5M
- Intratumoral SD-101 $4.5M
- DV281 $1.3M
- HEPLISAV-B $281,507
- rF1V $84,247
Payment Categories
- Food & Beverage $328,895
- Consulting $1.7M
- Travel & Lodging $19,600
- Research $22.5M
About Dynavax Technologies Corporation
Dynavax Technologies Corporation has made $24.9M in payments to 10,213 healthcare providers, recorded across 19,385 transactions in the CMS Open Payments database. In 2024, the company paid $530,474. The top product by payment volume is Heplisav-B ($11.8M).
Payments were distributed across 149 medical specialties. The top specialty by payment amount is Internal Medicine ($1.1M to 1,946 doctors).
Payment categories include: Food & Beverage ($328,895), Consulting ($1.7M), Research ($22.5M), Travel & Lodging ($19,600).
Dynavax Technologies Corporation is associated with 6 products in the CMS Open Payments database, including Heplisav-B, SD-101, and Intratumoral SD-101.